VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: ~79.4 million
Fully diluted: ~99.6 million
**************************
The market needs markers to assess the potential of emerging growth stories. VentriPoint isn't only putting up sign posts, its installed lights to mark the roadway!
The market needs markers to assess the potential of emerging growth stories. VentriPoint isn't only putting up sign posts, its installed lights to mark the roadway!
VPT's technology utilizing basic ultrasound images to create 3D images of the heart is at the pre-commercialization stage. Under the leadership of relatively new CEO and successful entrepreneur Dr. George Adams, the company was on the record that it would install 10 of its systems in 2011. The timetable has been dramatically expedited due to the interest from the cardiology community.
In its 2010 year end MD&A (Management Discussion & Analysis) and news release, the company noted the first 10 installations would be completed by the end of Q2 AND it would be building and installing more systems than projected.
"The Company currently has completed the installation of 4 VMS units, and is scheduling and
coordinating the installation of the remaining 6 systems by end of second quarter 2011. The Company’s VMS is currently installed at Hospital for Sick Children, Toronto, Canada; Children’s’ Medical Hospital, Omaha, Nebraska; Rikshospitalet, Oslo, Norway; and Oregon Health & Sciences in Portland, Oregon. The Company is prioritizing the six remaining sites based upon a number of factors, including, the nature of the clinical studies being considered and the timing to publish and present results. With the strong interest from additional new potentials institutions, the Company’s pipeline for VMS deployments is now in excess of its planned 10 sites through June 2011."
coordinating the installation of the remaining 6 systems by end of second quarter 2011. The Company’s VMS is currently installed at Hospital for Sick Children, Toronto, Canada; Children’s’ Medical Hospital, Omaha, Nebraska; Rikshospitalet, Oslo, Norway; and Oregon Health & Sciences in Portland, Oregon. The Company is prioritizing the six remaining sites based upon a number of factors, including, the nature of the clinical studies being considered and the timing to publish and present results. With the strong interest from additional new potentials institutions, the Company’s pipeline for VMS deployments is now in excess of its planned 10 sites through June 2011."
It must be noted that VentriPoint in a very short period of time has attracted high profile doctors to its Scientific Advisory Board, is receiving a growing list of independent endorsements and is moving faster on its business plan than expected. VPT is looking to sell 100 or more systems in 2012.
The core assertion of VPT and that which is now being independently verified is that its technology is equivalent to an MRI at significantly less cost. In addition, the VMS technology is quick versus the MRI procedure and as an "add-on" to ultrasound units, the potential global install base is massive.
Keep watch on this company that is currently trading between $0.15 and $0.20.
To read the MD&A go to www.sedar .com and the news release, click here.
